Theralase(R) Expands Clinical Team
TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and devel
AccesswireMay 2 07:00 ET
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage pharmaceutical company dedicated to the resear
AccesswireApr 24 07:00 ET
Theralase(R) Granted Canadian Cancer Vaccine Patent
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and dev
AccesswireApr 5 07:00 ET
Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q4 2023 Earnings Conference
The following is a summary of the Theralase Technologies Inc. (TLTFF) Q4 2023 Earnings Call Transcript:Financial Performance:Theralase Technologies reported a 6% YoY decrease in sales to $1.07 million
moomoo AIApr 3 13:30 ET · Conference Call
Theralase Technologies Reports FY Results
Seeking AlphaMar 27 10:52 ET
Theralase(R) Release's 4Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and de
AccesswireMar 27 07:00 ET
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
TORONTO, ON / ACCESSWIRE / March 26, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and deve
AccesswireMar 26 07:00 ET
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
TORONTO, ON / ACCESSWIRE / February 12, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
AccesswireFeb 12 07:00 ET
Theralase Technologies Shares Update on Phase II Bladder Cancer Study
Yahoo FinanceFeb 8 09:34 ET
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
AccesswireFeb 8 07:00 ET
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / February 5, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
AccesswireFeb 5 16:35 ET
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
Yahoo FinanceJan 15 07:00 ET
Theralase Technologies Reports Results for the Nine Month Period Ended September
Seeking AlphaNov 30, 2023 09:42 ET
Theralase Release's 3Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
AccesswireNov 29, 2023 18:30 ET
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
AccesswireNov 29, 2023 16:35 ET
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
TORONTO, ON / ACCESSWIRE / November 17, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
AccesswireNov 17, 2023 16:30 ET
Theralase(R) Announces Brokered LIFE Financing
TORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
AccesswireOct 23, 2023 17:55 ET
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
Post Study II Monitoring of Response, Optional Maintenance Study II Treatments and Central Pathology Laboratory Review OptimizedTORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase Technologies Inc
AccesswireOct 23, 2023 07:00 ET
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical stage pharmaceutical company that is dedicated to the r
AccesswireSep 29, 2023 07:00 ET
Theralase(R) Grants Stock Options
TORONTO, ON / ACCESSWIRE / September 21, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research an
AccesswireSep 21, 2023 16:35 ET
No Data
No Data